The text starts here.

News Release

Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.

2008 Release

December 15, 2008 FDA Approves Sedative-Hypnotic Agent LUSEDRA™ Injection
November 17, 2008 FDA Approves BANZEL™ (rufinamide) as Adjunctive Treatment for Lennox-Gastaut Syndrome
November 11, 2008 Eisai Completes Alliance Agreement with TorreyPines Therapeutics for Genetic Research Programs to Discover Genes Associated with LOAD
-New Agreement Signed for Eisai to Purchase Research Assets-
October 29, 2008 HOUSE OF LORDS REFUSES TO HEAR NICE'S APPEAL
October 16, 2008 FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
October 8, 2008 Eisai Introduces “Chocola BB® Drink bit”, New Pharmaceutical Drink for Acne and Skin Care
September 3, 2008 Eisai Introduces “Hotmin®” for Improving Peripheral Blood Circulation
August 24, 2008 FDA Approves ALOXI® (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
August 18, 2008 SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)
July 31, 2008 Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
July 30, 2008 Eisai China Inc. Signs License Agreement in China for alpha-Lipon 300 STADA® for Diabetic Neuropathic Pain
July 26, 2008 Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures -FDA's Not Approvable Letter Outlines Pathway to Potential Approval-
July 22, 2008 U.S. FEDERAL CIRCUIT COURT OF APPEALS FULLY UPHOLDS EISAI'S FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES
July 16, 2008 Antiosteoporotic drugs “Actonel® 17.5 mg tablets” and “Benet® 17.5 mg tablets” received approval for additional indication in patients with Paget's disease of bone: Both come in new packages.
July 9, 2008 ALOXI® (PALONOSETRON HCL) INJECTION AVAILABLE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
July 7, 2008 Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allocated
July 1, 2008 EISAI PROVIDES PRELIMINARY EFFICACY UPDATE ON EORTC PHASE III TRIAL OF DACOGEN® VERSUS SUPPORTIVE CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
July 1, 2008 Proton Pump Inhibitor ACIPHEX® 20 mg Receives Approval for Short-Term Treatment of GERD in Adolescents in United States
June 20, 2008 Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 19, 2008 Transfer of Subsidiary Stock
June 17, 2008 HUMIRA® Subcutaneous Injection 40mg Syringe 0.8mL Now Available for the Treatment of Rheumatoid Arthritis
May 29, 2008 Notification with Respect to Issuance of Unsecured Straight Bonds
May 29, 2008 Termination of marketing alliance of Breathe Right® nasal strips
May 22, 2008 NON-IONIC CONTRAST AGENTS, IOMERON® 350 AND IOMERON® 350 SYRINGE, RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING
May 16, 2008 E7389 Demonstrated Anti-tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
May 16, 2008 Eisai Presents 16 Papers Accepted for ASCO Annual Meeting Reporting the Latest Results from its Oncology Research
May 14, 2008 Notice on New Stock Issuance in the Form of Stock Options
May 12, 2008 Distribution of Ethical Drugs Bufferin 81mg Tablets & Bufferin 330mg Tablets
May 9, 2008 COURT OF APPEAL MAKES DECISION FOLLOWING RULING THAT NICE PROCESS ON ANTI-DEMENTIA MEDICINES UNFAIR
May 8, 2008 FDA ADVISORY COMMITTEE VOTES IN FAVOR OF APPROVAL OF FOSPROPOFOL DISODIUM INJECTION FOR SEDATION
May 7, 2008 Eisai Establishes a New Subsidiary in China for Marketing Support and Maintenance of Pharmaceutical Manufacturing Machinery
May 1, 2008 Eisai Gained Favourable Ruling by Court of Appeal, as NICE Process for Developing Guidance on Anti-dementia Medicines Ruled Unfair
April 24, 2008 Eisai Introduces “Chocola BB® Royal 2” Vitamin B2 Drink for Extreme Fatigue  A New Drink with Amino Acids and Reduced Calories
April 21, 2008 Notice of Revised Business Forecast for Fiscal Year Ended March 31, 2008, as a Result of Acquisition of MGI PHARMA, INC.
April 16, 2008 European Regulatory Agency Grants Orphan Status to Morphotek®'s FARLETUZUMAB (MORAb-003) and MORAb-009
April 16, 2008 HUMIRA® received approval for the treatment of rheumatoid arthritis in Japan
April 11, 2008 Status of the E2007 (perampanel) Development Program- Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications -
April 3, 2008 Eisai to Resume Clinical Study to Evaluate E2012 as a Potential Next Generation Alzheimer's Disease Treatment
March 29, 2008 Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept® Patent Infringement Lawsuit against Teva Pharmaceuticals
March 28, 2008 Notice Concerning Shelf Registration for Issuance of Stock Options
March 28, 2008 Notice Concerning Shelf Registration for Issuance of Straight Bonds
March 14, 2008 Eisai Submits Application for Aricept® Oral Jelly Formulation in Japan
March 13, 2008 Eisai and Sanko Junyaku introduce New KL-6 Test Kits for LUMIPULS® Systems for Detecting Marker of Interstitial Pneumonia
March 12, 2008 Ms Science and Eisai Sign Option Agreement for Sigma Agonist SA4503
March 3, 2008 FDA APPROVES ALOXI® (PALONOSETRON HCL) INJECTION FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
March 3, 2008 Vasolan® (Ischaemic Heart Disease Treatment) Received Approval for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia
March 1, 2008 FDA Grants Priority Review for ACIPHEX® sNDA for Short-Term Treatment of GERD in Adolescents
February 28, 2008 Eisai Launches New CHOCOLA BB Product Lines CHOCOLA® BB Lucent C and CHOCOLA® BB Lucent Cream for Blemishes and Brown Spots on Skin
February 13, 2008 Eisai and Accenture launch Clinical Data Management in India under global outsourcing agreement
February 1, 2008 Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
February 1, 2008 Eisai Decides Additional Study for Pariet® for New Indication of Non-Erosive Gastro-Esophageal Reflux Disease in Japan
January 29, 2008 Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNF-alpha Antibody
January 29, 2008 EISAI COMPLETES ACQUISITION OF MGI PHARMA
January 28, 2008 Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF-alpha Antibody
January 23, 2008 EISAI ANNOUNCES SATISFACTION OF CONDITIONS TO TENDER OFFER FOR MGI PHARMA SHARES

Back to Top